Related Experiment Video
Updated: Jun 11, 2026

10:43
siRNA Screening to Identify Ubiquitin and Ubiquitin-like System Regulators of Biological Pathways in Cultured Mammalian Cells
Published on: May 24, 2014
Factors affecting reproducibility between genome-scale siRNA-based screens
Nicholas J Barrows1, Caroline Le Sommer, Mariano A Garcia-Blanco
1Department of Molecular Genetics and Microbiology, Duke-NUS Graduate Medical School, Durham, NC, USA.
Journal of Biomolecular Screening
|July 14, 2010
Summary
RNA interference screening identifies host factors for yellow fever virus. Analysis methods significantly impact results, affecting reproducibility and hit list composition. Data sharing is recommended for functional genomics screens.
Area of Science:
- Genomics
- Virology
- Bioinformatics
Background:
- RNA interference (RNAi) screening is a key genomic technology for understanding gene function.
- Whole-genome RNAi screens are powerful tools for identifying host factors in viral infections.
Purpose of the Study:
- To evaluate factors influencing hit list composition and reproducibility in RNAi screening.
- To compare different analysis methodologies for whole-genome RNAi screens.
- To assess the reproducibility of siRNA screening over time.
Main Methods:
- Performed two identical whole-genome small interfering RNA (siRNA)-based screens for yellow fever virus host factors.
- Compared candidate hit lists generated by various statistical methods (sum rank, median absolute deviation, z-score, strictly standardized mean difference).
- Assessed intra- and inter-screen reproducibility using different analysis approaches.
Main Results:
- Analysis methodology significantly impacted hit list composition, with results ranging from 82 to 1140 members.
- Reproducibility varied widely (32% to 99%) depending on the analysis method used.
- Testing at least two independent siRNAs per gene product in primary screens enhances validation.
Conclusions:
- The choice of analysis methodology is critical and profoundly influences RNAi screening outcomes.
- Standardized data sharing of functional genome-scale screening data is crucial for validation and reproducibility.
- Methods to reduce false discovery at the primary screening stage are essential.

